Methylthioninium chloride Proveblue European Union - English - EMA (European Medicines Agency)

methylthioninium chloride proveblue

provepharm sas - methylthioninium chloride - methemoglobinemia - all other therapeutic products - acute symptomatic treatment of medicinal and chemical products- induced methaemoglobinaemia.methylthioninium chloride proveblue is indicated in adults, children and adolescents (aged 0 to 17 years old).

Lumeblue (previously known as Methylthioninium chloride Cosmo) European Union - English - EMA (European Medicines Agency)

lumeblue (previously known as methylthioninium chloride cosmo)

alfasigma s.p.a. - methylthioninium chloride - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Methylthioninium chloride Proveblue 50mg10ml solution for injection ampoules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

methylthioninium chloride proveblue 50mg10ml solution for injection ampoules

martindale pharmaceuticals ltd - methylthioninium chloride - solution for injection - 5mg/1ml

Methylthioninium Chloride Injection New Zealand - English - Medsafe (Medicines Safety Authority)

methylthioninium chloride injection

max health limited - methylthioninium chloride 1%{relative} ((as the trihydrate)) - solution for injection - 1% w/v - active: methylthioninium chloride 1%{relative} ((as the trihydrate)) excipient: water for injection

Methylthioninium chloride 10mg1ml solution for injection ampoules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

methylthioninium chloride 10mg1ml solution for injection ampoules

special order - methylthioninium chloride - solution for injection - 10mg/1ml

Methylthioninium chloride 40mg2ml solution for injection ampoules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

methylthioninium chloride 40mg2ml solution for injection ampoules

special order - methylthioninium chloride - solution for injection - 20mg/1ml

Methylthioninium chloride 4.2mg100ml irrigation solution bottles United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

methylthioninium chloride 4.2mg100ml irrigation solution bottles

special order - methylthioninium chloride - irrigation solution - 42microgram/1ml

Metiblo 10 mg/1 ml inj. sol. i.v. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

metiblo 10 mg/1 ml inj. sol. i.v. amp.

laboratoires sterop sa-nv - methylthioninium chloride 10 mg/ml - solution for injection - 10 mg/1 ml - methylthioninium chloride 10 mg/ml - methylthioninium chloride

Metiblo 50 mg/5 ml inj. sol. i.v. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

metiblo 50 mg/5 ml inj. sol. i.v. amp.

laboratoires sterop sa-nv - methylthioninium chloride 50 mg/5 ml - solution for injection - 50 mg/5 ml - methylthioninium chloride 10 mg/ml - methylthioninium chloride

PAROXETINE HYDROCHLORIDE tablet, film coated, extended release United States - English - NLM (National Library of Medicine)

paroxetine hydrochloride tablet, film coated, extended release

physicians total care, inc. - paroxetine hydrochloride (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine 12.5 mg - paroxetine hydrochloride extended-release tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine hydrochloride extended-release tablets in the treatment of a major depressive episode was established in two 12 week controlled trials of outpatients whose diagnoses corresponded to the dsm-iv category of major depressive disorder (see clinical pharmacology: clinical trials). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning and includes the presence of at least 5 of the following 9 symptoms during the same 2 week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impai